{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.57","upperLimit":"36","value":"10"},{"groupId":"OG001","lowerLimit":"3.5","upperLimit":"52","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Percent probability of being progression free six months following enrollment. Progression-free interval (PFI) will be calculated as the date of enrollment until the end PFI date, where that date is calculated as the date of disease progression, date of death, date of removal of all tumors by surgery or last patient contact, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28\n\npharmacological study: Optional correlative studies\n\nlaboratory biomarker analysis: Optional correlative studies","id":"OG000","title":"Group 1 Relapsed/Refractory Rhabdomyosarcoma"},{"description":"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28\n\npharmacological study: Optional correlative studies\n\nlaboratory biomarker analysis: Optional correlative studies","id":"OG001","title":"Group 2 Relapsed/Refractory Wilms Tumor"}],"paramType":"NUMBER","populationDescription":"All eligible patients are included in this analysis for both Rhabdomyosarcoma and Wilms Tumor. However, there were no accruals on the disease arms for Hepatocellular carcinoma and Papillary Thyroid carcinoma and were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"Six months after enrollment","title":"Progression-free Survival According to RECIST Version 1.1","type":"SECONDARY","unitOfMeasure":"percentage of probability"}